. 2020 Apr 15;11(6):1199–1216. doi: 10.1007/s13300-020-00816-y

Table 2.

GLP-1 monotherapy for obesity

Drug	Licensing	Maximum recommended dose	Weight loss
Exenatide [28]	Type 2 diabetes (FDA 2005; EMA 2006)	10 mcg twice daily, or 2 mg once weekly	10 mcg twice daily: 1.4 kg^a 2 mg once weekly: 1.6 kg^a
Liraglutide [16, 17, 28]	Type 2 diabetes (FDA 2010; EMA 2009); obesity (FDA 2014; EMA 2015)	T2D: ≤ 1.8 mg once daily Obesity: ≤ 3.0 mg once daily	1.8 mg once daily: 1.5 kg^a 3.0 mg once daily: 5.9 kg^a
Lixisenatide [30]	Type 2 diabetes (FDA 2016; EMA 2013)	20 mcg once daily	20 mcg daily: 2.0 kg^b
Dulaglutide [31]	Type 2 diabetes (FDA 2014; EMA 2014)	1.5 mg once weekly	1.5 mg weekly: 2.3 kg^b 0.75 mg weekly: 1.4 kg^b
Semaglutide [32]	Type 2 diabetes (FDA 2017; EMA 2018)	1.0 mg once weekly	1.0 mg weekly: 6.5 kg^b 0.5 mg weekly: 4.6 kg^b

Summarises the use and weight loss efficacy of available GLP-1 analogue monotherapy

^aAdditional weight loss compared with control

^bAbsolute weight loss